La chaîne d'options affiche les données clés des options sur actions de Vivesto à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Vivesto..

Vivesto (OTC:OASMY) Stock, Chaîne d'Options

Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments.

Vivesto AB

Truist Securities analyst David Smith maintains Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) with a Buy and raises the price target from $84 to $97.

News

Price Target

Analyst Ratings

SCHW

Truist Securities Maintains Buy on Charles Schwab, Raises Price Target to $97

Truist Securities analyst Jake Bartlett maintains Shake Shack (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHAK#NYSE">SHAK</a>) with a Buy and raises the price target from $134 to $140.

SHAK

Truist Securities Maintains Buy on Shake Shack, Raises Price Target to $140

Rumors

Trading Ideas

PLTR

Watching Palantir Technologies; Hearing Investor Business Daily SwingTrader Bought The Stock

RBC Capital analyst Luca Issi maintains Adverum Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADVM#NASDAQ">ADVM</a>) with a Sector Perform and lowers the price target from $5 to $4.

ADVM

RBC Capital Maintains Sector Perform on Adverum Biotechnologies, Lowers Price Target to $4

Truist Securities analyst Terry Tillman maintains Riskified (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSKD#NYSE">RSKD</a>) with a Buy and raises the price target from $7 to $8.

RSKD

Truist Securities Maintains Buy on Riskified, Raises Price Target to $8

https://about.fb.com/news/2025/05/advancing-accessibility-meta/#:~:text=Starting%20today%2C%20we're%20introducing,people%20ask%20about%20their%20environment.

Reported Earlier: Meta Platforms Says "You Can Now Customize Meta AI To Provide Detailed Responses On Ray-Ban Meta Glasses, A Feature That's Built To Assist Everyone, But Can Have Particular Value To People With Disabilities"

DA Davidson analyst Gil Luria maintains Dynatrace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DT#NYSE">DT</a>) with a Buy and raises the price target from $60 to $65.

DA Davidson Maintains Buy on Dynatrace, Raises Price Target to $65

Truist Securities analyst Scot Ciccarelli maintains European Wax Center (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWCZ#NASDAQ">EWCZ</a>) with a Buy and raises the price target from $5 to $6.

EWCZ

Truist Securities Maintains Buy on European Wax Center, Raises Price Target to $6

WIIM

PNBK

Patriot National Bancorp shares are trading lower after the company announced a $250 million mixed shelf offering.

DA Davidson analyst Rudy Kessinger maintains Okta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) with a Buy and raises the price target from $125 to $145.

OKTA

DA Davidson Maintains Buy on Okta, Raises Price Target to $145

CTXR

Citius Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q2 EPS results.

EDBL

Edible Garden shares are trading lower after the company reported mixed Q1 financial results.

Exclusives

EXCLUSIVE: Hightower Advisors' Stephanie Link Says 'Added KKR this past week w the stock down 15% ytd and a play on growth, real assets, infrastructure and fee growth.'; Says 'BA has been my favorite stock for 2025'

PAVM

PAVmed shares are trading lower after the company reported a year-over-year decrease in Q1 sales results.

<a href="https://www.bloomberg.com/news/articles/2025-05-15/thoma-bravo-is-said-to-sell-remaining-3-4-billion-nasdaq-stake" title="https://www.bloomberg.com/news/articles/2025-05-15/thoma-bravo-is-said-to-sell-remaining-3-4-billion-nasdaq-stake">https://www.bloomberg.com/news/articles/2025-05-15/thoma-bravo-is-said-to-sell-remaining-3-4-billion-nasdaq-stake</a>

NDAQ

'Thoma Bravo Sells Remaining $3.4 Billion Nasdaq Stake' - Bloomberg News

DA Davidson analyst Gil Luria maintains Riskified (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSKD#NYSE">RSKD</a>) with a Buy and raises the price target from $6 to $6.5.

DA Davidson Maintains Buy on Riskified, Raises Price Target to $6.5

FONR

Fonar shares are trading higher after the company reported a year-over-year increase in Q3 financial results.

RBC Capital analyst Brian Abrahams maintains Aardvark Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AARD#NASDAQ">AARD</a>) with a Outperform and lowers the price target from $21 to $20.

Comments

Vivesto

Vivesto (OASMY) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL